As cortical amyloid deposition and plasma p‐tau elevations are among the earliest detectable markers of AD pathology, astrocyte reactivity may represent a promising target for early intervention11 or explain, in part, cases with discordant AD biomarkers (e.g., Aβ‐PET positive, plasma p‐tau negative).44 The gene discussed is MAPT; the disease is Alzheimer disease.